Population pharmacokinetics and exposure-response of albinterferon alfa-2b

Matthew M. Riggs, Timothy T. Bergsma, James A. Rogers, Marc R. Gastonguay, G. Mani Subramanian, Cecil Chen, Matt Devalaraja, Alfred E. Corey, Haiying Sun, Jing Yu, Daniel S. Stein

Research output: Contribution to journalArticle

Abstract

Albinterferon alfa-2b (albIFN) has been studied for treatment of chronic hepatitis C virus (HCV). A population pharmacokinetics model was developed using nonlinear mixed-effects modeling. Efficacy/safety exposure-response relationships were assessed for subcutaneous albIFN doses (900-1800 μg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin. Sustained virologic response (SVR) exposure-response was modeled using logistic regression. Adverse event incidence was tabulated versus exposure quartiles. First-order absorption rate constant (0.0148 hü'1), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively. Residual variance estimates were 27% (coefficient of variation) and 1.51 ng/mL (standard deviation). For the only explanatory covariate-body weight-exposure decreased as weight increased. Important SVR predictors included baseline HCV RNA, fibrosis score, and black race (genotype 1); SVR was minimally related to exposure. Most adverse events had similar incidence rates across exposure quartiles. Some adverse events had a higher incidence in the upper exposure quartile without evidence of exposure-response across the lower quartiles. Given the lack of consistent efficacy/safety exposure-response relationships, further investigation is necessary to optimize albIFN dosing.

Original languageEnglish (US)
Pages (from-to)475-486
Number of pages12
JournalJournal of Clinical Pharmacology
Volume52
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Hepacivirus
Pharmacokinetics
Genotype
Incidence
Population
Safety
Ribavirin
Chronic Hepatitis C
Fibrosis
Logistic Models
Body Weight
RNA
Weights and Measures
albinterferon alfa-2b
Sustained Virologic Response
Therapeutics

Keywords

  • albIFN
  • albinterferon alfa-2b
  • chronic hepatitis C virus
  • exposure-response
  • population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Riggs, M. M., Bergsma, T. T., Rogers, J. A., Gastonguay, M. R., Subramanian, G. M., Chen, C., ... Stein, D. S. (2012). Population pharmacokinetics and exposure-response of albinterferon alfa-2b. Journal of Clinical Pharmacology, 52(4), 475-486. https://doi.org/10.1177/0091270011399576

Population pharmacokinetics and exposure-response of albinterferon alfa-2b. / Riggs, Matthew M.; Bergsma, Timothy T.; Rogers, James A.; Gastonguay, Marc R.; Subramanian, G. Mani; Chen, Cecil; Devalaraja, Matt; Corey, Alfred E.; Sun, Haiying; Yu, Jing; Stein, Daniel S.

In: Journal of Clinical Pharmacology, Vol. 52, No. 4, 04.2012, p. 475-486.

Research output: Contribution to journalArticle

Riggs, MM, Bergsma, TT, Rogers, JA, Gastonguay, MR, Subramanian, GM, Chen, C, Devalaraja, M, Corey, AE, Sun, H, Yu, J & Stein, DS 2012, 'Population pharmacokinetics and exposure-response of albinterferon alfa-2b', Journal of Clinical Pharmacology, vol. 52, no. 4, pp. 475-486. https://doi.org/10.1177/0091270011399576
Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C et al. Population pharmacokinetics and exposure-response of albinterferon alfa-2b. Journal of Clinical Pharmacology. 2012 Apr;52(4):475-486. https://doi.org/10.1177/0091270011399576
Riggs, Matthew M. ; Bergsma, Timothy T. ; Rogers, James A. ; Gastonguay, Marc R. ; Subramanian, G. Mani ; Chen, Cecil ; Devalaraja, Matt ; Corey, Alfred E. ; Sun, Haiying ; Yu, Jing ; Stein, Daniel S. / Population pharmacokinetics and exposure-response of albinterferon alfa-2b. In: Journal of Clinical Pharmacology. 2012 ; Vol. 52, No. 4. pp. 475-486.
@article{846912e485d5487e9295cf5f1835556a,
title = "Population pharmacokinetics and exposure-response of albinterferon alfa-2b",
abstract = "Albinterferon alfa-2b (albIFN) has been studied for treatment of chronic hepatitis C virus (HCV). A population pharmacokinetics model was developed using nonlinear mixed-effects modeling. Efficacy/safety exposure-response relationships were assessed for subcutaneous albIFN doses (900-1800 μg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin. Sustained virologic response (SVR) exposure-response was modeled using logistic regression. Adverse event incidence was tabulated versus exposure quartiles. First-order absorption rate constant (0.0148 h{\"u}'1), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21{\%}, 34{\%}, and 24{\%}, respectively. Residual variance estimates were 27{\%} (coefficient of variation) and 1.51 ng/mL (standard deviation). For the only explanatory covariate-body weight-exposure decreased as weight increased. Important SVR predictors included baseline HCV RNA, fibrosis score, and black race (genotype 1); SVR was minimally related to exposure. Most adverse events had similar incidence rates across exposure quartiles. Some adverse events had a higher incidence in the upper exposure quartile without evidence of exposure-response across the lower quartiles. Given the lack of consistent efficacy/safety exposure-response relationships, further investigation is necessary to optimize albIFN dosing.",
keywords = "albIFN, albinterferon alfa-2b, chronic hepatitis C virus, exposure-response, population pharmacokinetics",
author = "Riggs, {Matthew M.} and Bergsma, {Timothy T.} and Rogers, {James A.} and Gastonguay, {Marc R.} and Subramanian, {G. Mani} and Cecil Chen and Matt Devalaraja and Corey, {Alfred E.} and Haiying Sun and Jing Yu and Stein, {Daniel S.}",
year = "2012",
month = "4",
doi = "10.1177/0091270011399576",
language = "English (US)",
volume = "52",
pages = "475--486",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Population pharmacokinetics and exposure-response of albinterferon alfa-2b

AU - Riggs, Matthew M.

AU - Bergsma, Timothy T.

AU - Rogers, James A.

AU - Gastonguay, Marc R.

AU - Subramanian, G. Mani

AU - Chen, Cecil

AU - Devalaraja, Matt

AU - Corey, Alfred E.

AU - Sun, Haiying

AU - Yu, Jing

AU - Stein, Daniel S.

PY - 2012/4

Y1 - 2012/4

N2 - Albinterferon alfa-2b (albIFN) has been studied for treatment of chronic hepatitis C virus (HCV). A population pharmacokinetics model was developed using nonlinear mixed-effects modeling. Efficacy/safety exposure-response relationships were assessed for subcutaneous albIFN doses (900-1800 μg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin. Sustained virologic response (SVR) exposure-response was modeled using logistic regression. Adverse event incidence was tabulated versus exposure quartiles. First-order absorption rate constant (0.0148 hü'1), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively. Residual variance estimates were 27% (coefficient of variation) and 1.51 ng/mL (standard deviation). For the only explanatory covariate-body weight-exposure decreased as weight increased. Important SVR predictors included baseline HCV RNA, fibrosis score, and black race (genotype 1); SVR was minimally related to exposure. Most adverse events had similar incidence rates across exposure quartiles. Some adverse events had a higher incidence in the upper exposure quartile without evidence of exposure-response across the lower quartiles. Given the lack of consistent efficacy/safety exposure-response relationships, further investigation is necessary to optimize albIFN dosing.

AB - Albinterferon alfa-2b (albIFN) has been studied for treatment of chronic hepatitis C virus (HCV). A population pharmacokinetics model was developed using nonlinear mixed-effects modeling. Efficacy/safety exposure-response relationships were assessed for subcutaneous albIFN doses (900-1800 μg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin. Sustained virologic response (SVR) exposure-response was modeled using logistic regression. Adverse event incidence was tabulated versus exposure quartiles. First-order absorption rate constant (0.0148 hü'1), apparent clearance (38.9 mL/h), and apparent volume of distribution (11.6 L) had interindividual variances (coefficient of variation) of 21%, 34%, and 24%, respectively. Residual variance estimates were 27% (coefficient of variation) and 1.51 ng/mL (standard deviation). For the only explanatory covariate-body weight-exposure decreased as weight increased. Important SVR predictors included baseline HCV RNA, fibrosis score, and black race (genotype 1); SVR was minimally related to exposure. Most adverse events had similar incidence rates across exposure quartiles. Some adverse events had a higher incidence in the upper exposure quartile without evidence of exposure-response across the lower quartiles. Given the lack of consistent efficacy/safety exposure-response relationships, further investigation is necessary to optimize albIFN dosing.

KW - albIFN

KW - albinterferon alfa-2b

KW - chronic hepatitis C virus

KW - exposure-response

KW - population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84859073010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859073010&partnerID=8YFLogxK

U2 - 10.1177/0091270011399576

DO - 10.1177/0091270011399576

M3 - Article

C2 - 21551316

AN - SCOPUS:84859073010

VL - 52

SP - 475

EP - 486

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -